Piper Sandler initiated coverage of Climb Bio (CLYM) with an Overweight rating and $23 price target The company is developing budoprutug across three indications and CLYM116 in Berger’s disease, the analyst tells investors in a research note. Piper says Climb Bio has “multiple shots on goal to unlock significant value” heading into a catalyst-rich 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM:
- Ten new option listings and two option delistings on January 22nd
- Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch
- Climb Bio outlines 2026 clinical milestones and cash runway
- Climb Bio announces pipeline progress, priorities for FY26
- Climb Bio Challenges Alumis Milestone and Royalty Obligations